Search results
Antimalarial agents are the first-line therapy for all types of cutaneous lupus erythematosus. A clinical effect may be seen as early 2 weeks; if there is no change in 12 weeks, therapy should be escalated. Combination therapy of 2 antimalarial agents (HCQ + CQ) or quinacrine can be tried first.
A young woman with systemic lupus erythematosus on hydroxychloro-quine, mycophenolate mofetil, and prednisone presented to the dermatology clinic with a 3-week history of a bullous eruption involving the face, oral mucosa, el-bows, and hands (Figure 1).
21 paź 2022 · In clinical trials, voclosporin has been shown to be effective in treating lupus. Other potential drugs to treat lupus are currently being studied, including abatacept (Orencia), anifrolumab and others.
The mainstay of therapy is judicious use of immunosuppressive medications. Long-term follow-up to address morbidity arising from treatment complications, disease damage, and increased cardiovascular risk is essential.
22 maj 2023 · This activity reviews the evaluation and management of bullous systemic lupus erythematosus and highlights the role of the interprofessional team in improving care for patients with this condition. Objectives: Outline the typical presentation of a patient with bullous systemic lupus erythematosus.
11 maj 2022 · Bullous systemic lupus erythematosus (BSLE), an autoimmune bullous condition and a manifestation of SLE, is an acquired subepidermal blistering disease . It is a rare cutaneous manifestation of SLE, accounting for <5% of the cutaneous lupus lesions, and is most commonly seen in females of African descent in their second to the fourth decade of ...
31 paź 2014 · Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus erythematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
